BioDelivery Sciences to Report Second Quarter 2020 Financial Results on August 5, 2020
Rhea-AI Summary
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will report its Q2 2020 financial results on August 5, 2020, before U.S. markets open. A conference call is scheduled for 8:30 AM ET to discuss these results and provide updates on operations. The company focuses on chronic conditions and leverages its proprietary BEMA® technology for product development. BDSI offers solutions for conditions like chronic pain and opioid-induced constipation, ensuring comprehensive care for patients.
AI-generated analysis. Not financial advice.
Positive
- Scheduled Q2 2020 financial results report could highlight positive operational metrics.
- Strong focus on chronic conditions may indicate growth potential in a specialized market.
Negative
- None.
News Market Reaction – BDSI
On the day this news was published, BDSI declined 0.48%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
RALEIGH, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its second quarter 2020 financial results before the open of the U.S. financial markets on Wednesday, August 5, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, August 5, 2020 |
| Time: | 8:30 AM Eastern Time |
| Domestic: | 866-248-8441 |
| International: | 720-452-9102 |
| Conference ID: | 9339657 |
| Webcast: | http://public.viavid.com/index.php?id=141000 |
About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
© 2020 BioDelivery Sciences International, Inc. All rights reserved.
Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com